Implementation of inpatient models of pharmacogenetics programs

American Journal of Health-System Pharmacy

Volumn 73, Issue 23, 2016, Pages 1944-1954

  Cavallari, Larisa H ^a   Lee, Craig R ^b   Duarte, Julio D ^c,d   Nutescu, Edith A ^c,d   Weitzel, Kristin W ^a   Stouffer, George A ^e   Johnson, Julie A ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b University of North Carolina   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d UNIVERSITY OF ILLINOIS HOSPITAL AND HEALTH SCIENCES SYSTEM   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Clopidogrel; Genotype; Inpatient; Pharmacists; Pharmacogenetics; Warfarin

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; VITAMIN K EPOXIDE REDUCTASE; WARFARIN;

ARTICLE; GENETIC SCREENING; GENOTYPE; HEALTH EDUCATION; HOSPITAL PATIENT; HUMAN; OUTCOME ASSESSMENT; PATIENT SAFETY; PHARMACIST; PHARMACOGENETICS; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; QUALITY CONTROL; HOSPITAL PHARMACY; HOSPITALIZATION; PATIENT CARE; PROCEDURES; PROFESSIONAL STANDARD; PROGRAM DEVELOPMENT; TRENDS;

GENOTYPE; HOSPITALIZATION; HUMANS; PATIENT CARE TEAM; PHARMACOGENETICS; PHARMACY SERVICE, HOSPITAL; PROFESSIONAL ROLE; PROGRAM DEVELOPMENT;

EID: 84995900460     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp150946     Document Type: Article

References (48)

1. Leape LL, Brennan TA, Laird N et al. The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. N Engl J Med. 1991; 324:377-84.
2. Fanikos J, Cina JL, Baroletti S et al. Adverse drug events in hospitalized cardiac patients. Am J Cardiol. 2007; 100:1465-9.
3. Classen DC, Pestotnik SL, Evans RS et al. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA. 1997; 277:301-6.
4. American Society of Health-System Pharmacists. ASHP statement on the pharmacist's role in clinical pharma-cogenomics. Am J Health-Syst Pharm. 2015; 72:579-81.
5. Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther. 2011; 89:464-7.
6. Mega JL, Close SL, Wiviott SD et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009; 360:354-62.
7. Momary KM, Dorsch M P, Bates ER. Genetic causes of clopidogrel nonresponsiveness: which ones really count? Pharmacotherapy. 2010; 30:265-74.
8. Scott SA, Sangkuhl K, Stein CM et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013; 94:317-23.
9. Mega JL, Simon T, Collet JP et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a metaanalysis. JAMA. 2010; 304:1821-30.
10. Sorich MJ, Rowland A, McKinnon RA, Wiese MD. CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis. Circ Cardiovasc Genet. 2014; 7:895-902.
11. Holmes DR Jr, Dehmer GJ, Kaul S et al. ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol. 2010; 56:321-41.
12. Mega JL, Close SL, Wiviott SD et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation. 2009; 119:2553-60.
13. Wallentin L, James S, Storey RF et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010; 376:1320-8.
14. Wadelius M, Chen LY, Lindh JD et al. The largest prospective warfarintreated cohort supports genetic forecasting. Blood. 2009; 113:784-92.
15. Johnson JA, Gong L, Whirl-Carrillo M et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther. 2011; 90:625-9.
16. Lindh JD, Holm L, Andersson ML, Rane A. Influence of CYP2C9 genotype on warfarin dose requirements - a systematic review and meta-analysis. Eur J Clin Pharmacol. 2009; 65:365-75.
17. Cavallari LH, Perera MA. The future of warfarin pharmacogenetics in underrepresented minority groups. Future Cardiol. 2012; 8:563-76.
18. Cavallari LH, Langaee TY, Momary KM et al. Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin Pharmacol Ther. 2010; 87:459-64.
19. Niinuma Y, Saito T, Takahashi M et al. Functional characterization of 32 CYP2C9 allelic variants. Pharmacogenomics J. 2014; 14:107-14.
20. Rieder MJ, Reiner A P, Gage BF et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005; 352:2285-93.
21. Caldwell MD, Awad T, Johnson JA et al. CYP4F2 genetic variant alters required warfarin dose. Blood. 2008; 111:4106-12.
22. McDonald MG, Rieder MJ, Nakano M et al. CYP4F2 is a vitamin K1 oxidase: an explanation for altered warfarin dose in carriers of the V433M variant. Mol Pharmacol. 2009; 75:1337-46.
23. Mega JL, Walker JR, Ruff CT et al. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015; 385:2280-7.
24. Pirmohamed M, Burnside G, Eriksson N et al. A randomized trial of genotypeguided dosing of warfarin. N Engl J Med. 2013; 369:2294-303.
25. Kimmel SE, French B, Kasner SE et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med. 2013; 369:2283-93.
26. Johnson JA, Cavallari LH. Warfarin pharmacogenetics. Trends Cardiovasc Med. 2015; 25:33-41.
27. Perera MA, Cavallari LH, Limdi NA et al. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet. 2013; 382:790-6.
28. Drozda K, Wong S, Patel SR et al. Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans. Pharmacogenet Genomics. 2015; 25:73-81.
29. Nutescu E, Duarte J, Cheng W et al. Novel genotype guided personalized warfarin service improves outcomes in an ethnically diverse population. Circulation. 2014; 130:A16119.
30. Nutescu EA, Drozda K, Bress AP et al. Feasibility of implementing a comprehensive warfarin pharmacogenetics service. Pharmacotherapy. 2013; 33:1156-64.
31. Weitzel KW, Elsey AR, Langaee TY et al. Clinical pharmacogenetics implementation: approaches, successes, and challenges. Am J Med Genet C Semin Med Genet. 2014; 166C:56-67.
32. Lee JA, Lee CR, Reed BN et al. Implementation and evaluation of a CYP2C19 genotype-guided antiplatelet therapy algorithm in high-risk coronary artery disease patients. Pharmacogenomics. 2015; 16:303-13.
33. Owusu-Obeng A, Weitzel KW, Hatton RC et al. Emerging roles for pharmacists in clinical implementation of pharmacogenomics. Pharmacotherapy. 2014; 34:1102-12.
34. Kisor D F, Bright DR, Chen J, Smith TR. Academic and professional pharmacy eduction: a pharmacogenomics certificate training program. Pers Med. 2015; 12:563-73.
35. Zembles T. An inservice program on pharmacogenetics to individualize drug therapy. Am J Pharm Educ. 2010; 74:10.
36. Formea CM, Nicholson WT, McCullough KB et al. Development and evaluation of a pharmacogenomics educational program for pharmacists. Am J Pharm Educ. 2013; 77:10.
37. Whirl-Carrillo M, McDonagh EM, Hebert JM et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012; 92:414-7.
38. Caudle KE, Klein TE, Hoffman JM et al. Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab. 2014; 15:209-17.
39. Food and Drug Administration. Nucleic acid based tests. www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm330711.htm (accessed 2015 Oct 26).
40. Valdes R, Payne DA, Linder MW. Laboratory analysis and application of pharmacogenetics to clinical practice. Washington, DC: National Academy of Clinical Biochemistry; 2010:15.
41. Crews KR, Cross SJ, McCormick JN et al. Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am J Health-Syst Pharm. 2011; 68:143-50.
42. Oetjens MT, Denny JC, Ritchie MD et al. Assessment of a pharmacogenomic marker panel in a polypharmacy population identified from electronic medical records. Pharmacogenomics. 2013; 14:735-44.
43. Cavallari LH, Magvanjav O, Anderson RD et al. Clinical implementation of CYP2C19 genotype guided antiplatelet therapy reduces cardiovascular events after PCI. Circulation. 2015; 132:A11802.
44. Price MJ, Murray SS, Angiolillo DJ et al. Influence of genetic polymor-phisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study. J Am Coll Cardiol. 2012; 59:1928-37.
45. Levine GN, Bates ER, Blankenship JC et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011; 124:e574-651.
46. Hoffman JM, Haidar CE, Wilkinson MR et al. PG4KDS: a model for the clinical implementation of preemptive pharmacogenetics. Am J Med Genet C Semin Med Genet. 2014; 166C:45-55.
47. Pulley JM, Denny JC, Peterson JF et al. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin Pharmacol Ther. 2012; 92:87-95.
48. Shuldiner AR, Palmer K, Pakyz RE et al. Implementation of pharmacogenetics: the University of Maryland Personalized Anti-platelet Pharmacogenetics Program. Am J Med Genet C Semin Med Genet. 2014; 166C:76-84.